Find information on Industry Analysis Report

Posts tagged ‘Medicine’

Forecast and analysis on the Multiple Sclerosis Market

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:
* An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
* A detailed forecast data analysis spreadsheet model comparing critical market parameters including
* Timely event-driven market forecast report and data analysis updates over the next 12 months

Mapping Future Events to Product Sales Forecasts
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006–11) is based on company information, and the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Report features:
* Historical MS sales from 2006–2011
* Forecast MS sales from 2012-2016
* Key competitors and drug developers
* Predicted product positioning
* Current and late-stage pipeline drugs
* Future event mapping to forecast data points
* Comparative clinical trial results

Interactive Product and Market Forecast Data Model
FirstWord’s MS forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.
* Market size
* Product sales
* Company forecasts
* Company, brand, and drug class
* Mechanism of action
* Future events

Forecasts and Analysis Updated Within Days of Major Market Events
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.

Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.

Understand the Unique Benefits of Consensus Outlook Evaluate future sales forecasts and predicted market growth Map your market parameters and chart commercial prospects Assess market share by company and product Tailor your strategic and investment focus based on the competition Set proactive launch and branding strategies Keep up with event-driven market data updates

For more information kindly visit :
Report on Therapy Trends: Multiple Sclerosis – KOL Insight and Consensus Outlook Modules

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Therapy Trends: Multiple Sclerosis

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.

Multiple Sclerosis: On the cusp of a treatment revolution
The year 2012 will see landmark changes in the treatment of MS. Gilenya, the first novel drug in five years, is to be joined by three new products; BG-12 from Biogen Idec, Sanofi’s Aubagio and Genzyme’s Lemtrada. These drugs will partially satisfy substantial unmet needs of convenient administration and more efficacious therapy to drive unprecedented market growth.

Driven by in-depth interviews with the world’s leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Drive your strategic decision-making with inside intelligence

Therapy Trends: Multiple Sclerosis disseminates critical opinion and analysis to provide premier research.
* We cut to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time
* Our unique thought-leader selection matrix identifies the most influential KOLs in MS to deliver the perspectives vital in giving you a competitive edge, enabling informed decision-making and planning
* Detailed analysis of marketed and pipeline drugs helps you understand the products that will shape the future MS market
* KOL consensus on the future treatment algorithm offers a window into the future changes in medical evidence and clinical practice
* Uncovering KOLs’ opinions on unmet needs enables you to identify potential commercial opportunities
* Dynamic report updates evaluate the market impact of key events from KOL perspectives, allowing you to react to significant MS market developments within days of events occurring

Critical questions answered
Our MS KOLs are selected according to their level of engagement and influence within the pharmaceutical industry and their scientific standing. FirstWord’s unique KOL scoring system enables identification of KOLs with the greatest knowledge of how MS treatment will evolve and shape the future landscape.

* What are the key unmet needs? There is a high risk, high reward opportunity in the development of a therapy with efficacy for progressive subtypes.
* How will therapies will be positioned against each other in the future of MS treatment? Biogen’s new oral therapy BG-12 is expected to usurp the current market leaders and become the first-line therapy of choice.
* How will treatment developments play out in the near future? Biogen’s activity in broadening its robust pipeline shows its resolve in maintaining its leading position in MS.
* Is there potential for new players in the lucrative MS market? New entrants are set to capture significant share and cannibalise sales of the leading drugs.
* Where will Sanofi’s Lemtrada and Aubagio be positioned in treatment? Pricing and safety will play a large part in determining uptake of this highly effective drug
* How will the launch of biosimilars affect prescribing behavior? Pricing will be a key determinant in positioning and uptake
* How will Novartis’s Gilenya be affected by recent safety concerns? Long-term concerns have kept it from being the first line therapy.
* Will the new John Cunningham Virus test encourage earlier adoption of Tysabri? This offers the first example of personalised medicine; a trend that will aid uptake in future.

For more information kindly visit :
Report on Therapy Trends: Multiple Sclerosis

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Consensus Outlook: Multiple Sclerosis

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

* An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
* A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2006 to 2016
* Timely event-driven market forecast report and data analysis updates over the next 12 months

Understand the Unique Benefits of Consensus Outlook
* Evaluate future sales forecasts and predicted market growth
* Map your market parameters and chart commercial prospects
* Assess market share by company and product
* Tailor your strategic and investment focus based on the competition
* Set proactive launch and branding strategies
* Keep up with event-driven market data updates

Mapping Future Events to Product Sales Forecasts
The forecast analysis report component of Consensus Outlook: Multiple Sclerosis delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2006–11) is based on company information, and the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.

Report features:
* Historical MS sales from 2006–2011
* Forecast MS sales from 2012-2016
* Key competitors and drug developers
* Predicted product positioning
* Current and late-stage pipeline drugs
* Future event mapping to forecast data points
* Comparative clinical trial results

An approach backed by unrivalled knowledge and market intimacy
For each Therapy Trends report, FirstWord analysts produce a data analysis module, a Consensus Outlook, which provides annual historical and forecast, product-level sales data. Historical sales data is derived from company information, while the five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.

Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections – produced either internally or by other third parties – can be assessed.

For more information kindly visit :
Report on Consensus Outlook: Multiple Sclerosis

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021

What are the commercial prospects for pharmaceutical anti-counterfeiting technology? Our new report shows you that industry and market’s revenue potential from 2011 to 2021.

There, you will assess anti-counterfeiting technologies, seeing trends and opportunities. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our report shows you revenue prospects for pharma anti-counterfeiting technologies at total world, submarket and national levels to 2021. We discuss the anti-counterfeiting activities of companies such as Pfizer, J&J, GSK, Sanofi-Aventis, Novartis and AstraZeneca.

We also discuss the activities and potential of anti-counterfeiting specialists, such as NanoGuardian, Ahura Scientific, TruTag Technologies, Colorcon, Authentix, 3M, Cortegra and Covectra.
Our study forecasts revenues for radio frequency identification (RFID), pharmaceutical taggant, hologram/OVD, security ink and watermark technologies to 2021. You will see their market potentials.
Which pharma anti-counterfeiting technologies and national markets will provide the best opportunities from 2011 to 2021? What effects will governmental policies have? Our work gives answers you need.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Industry and market analysis to help your work – so you won’t be left behind

Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP analysis, review of companies and product developments, and opinions from our survey.
We include 67 tables and charts and three research interviews (shown in the accompanying lists). Our study helps you to understand pharma anti-counterfeiting activities this decade.
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
• You will receive hard data for the pharmaceutical anti-counterfeiting industry and market from 2010 to 2021
• You will discover revenue forecasting for the overall world market to 2021
• You will see revenue predictions for leading technologies – RFID, taggants, holograms/OVDs, security inks and watermarks – to 2021
• You will assess anti-counterfeiting needs at world and regional level
• You will find revenue predictions for leading geographical markets to 2021 (US, UK, Germany, France, Japan, Italy, Canada, Spain, China and India)
• You will assess the implications of government mandates for product serialisation, seeing how these will affect the activities of pharma companies
• You will assess leading companies in pharma anti-counterfeiting, discovering their activities, potential and commercial outlooks for the future
• You will examine research and development, as well as up-and-coming technologies for tackling drug counterfeiting
• You will investigate competition and opportunities that will influence revenues
• You will see what will stimulate and restrain the industry and market
• You will analyse opportunities for established companies and those seeking to enter the anti-counterfeiting technologies market
• You will view opinion from our survey, including full interview transcripts.

That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge.
Order our report now to gain industry and market information you need
Our report can benefit everybody interested in pharmaceutical anti-counterfeiting technologies. We give predictions and answers you need. Don’t miss out – please order our report now.

For more information kindly visit :
Report on Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Buyer Spend Activity and Procurement Behaviors and Strategies in the Pharmaceutical Industry

• Analysis of opinions drawn from leading pharmaceutical industry executives.
• Analysis on how procurement expenditure, business strategies and practices in the pharmaceutical industry are set to change in 2011–2012.
• Analysis on spending plans, budget allocations, challenges and investment opportunities of purchase decision makers.

Summary
This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. It analyzes how procurement expenditure, business strategies and practices are set to change in the pharmaceutical industry in 2012–13. This report gives you access to the category-level spending outlooks, budgets, supplier selection criteria, business challenges and investment opportunities for leading purchase decision makers. The report also identifies future growth of buyers and suppliers and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by region, company type and size.

Scope
• The opinions and forward looking statements of 247 industry executives have been captured in our in-depth survey, of which 51% represent Director and C-level respondents.
• The research is based on primary survey research conducted by ICD Research accessing its B2B panels comprised of senior purchase decision makers and leading supplier organizations.
• The geographical scope of the research is global – drawing on the activity and expectations of leading industry players across the Americas, Europe, Asia-Pacific, Africa and Middle East.
• Key topics covered include buyer expenditure activity, procurement behaviors and strategies, threats and opportunities, economic outlook and business confidence.
• In the report, buyers identify what suppliers need to do to maintain their business and the key actions being taken by industry players to overcome the leading business threats.
• The report examines current practices and provides future expectations for the industry over the next 12-24 months.

Reasons To Buy
• This report will help you to drive revenues by understanding future product investment areas and growth regions.
• This report will help you to formulate effective sales and marketing strategies by identifying how buyer budgets are changing and the direction of spend in the future.
• This report will help you to better promote your business by aligning your capabilities and business practices with your customer’s changing needs.
• This report will help you to secure stronger customer relationships by understanding the leading business concerns and changing strategies of industry buyers.
• This report will help you to predict how the industry will grow, consolidate and where it will stagnate.
• This report will help you to uncover the business outlook, key challenges and opportunities identified by suppliers and buyers.

Table of Contents
1 Introduction
1.1 What is This Report About?
1.2 Definitions
1.3 Methodology
1.4 Profile of Survey Respondents: Global Pharmaceutical Industry
1.4.1 Profile of buyer respondents: global pharmaceutical industry
1.4.2 Profile of supplier respondents: global pharmaceutical industry
2 Executive Summary
3 Global Pharmaceutical Industry Buyer Spend Activity
3.1 Global Pharmaceutical Industry: Annual Procurement Budgets
3.1.1 Global pharmaceutical industry: annual procurement budgets by company type
3.1.2 Global pharmaceutical industry: annual procurement budgets by region
3.1.3 Global pharmaceutical industry: annual procurement budgets by company turnover
3.2 Global Pharmaceutical Industry: Planned Change in Procurement Spend
3.2.1 Global pharmaceutical industry: planned change in procurement spend by buyer type
3.2.2 Global pharmaceutical industry: planned change in procurement spend by region
3.2.3 Global pharmaceutical industry: planned change in procurement spend by company turnover
3.2.4 Global pharmaceutical industry: planned change in expenditure vs. revenue growth optimism
3.2.5 Global pharmaceutical industry: planned change in expenditure vs. cost containment
3.2.6 Global pharmaceutical industry: planned change in procurement spend – cross industry comparisons

For more information kindly visit :
Report on Buyer Spend Activity and Procurement Behaviors and Strategies in the Pharmaceutical Industry

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Viral Partnering Terms and Agreements

The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies.

The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.

* Trends in viral partnering deals
* Average deal terms for headline, upfront and royalty by stage of development
* Viral partnering agreement structure
* Viral partnering contract documents
* Top viral deals by value
* Most active viral dealmakers

Description

The Viral Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the viral partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter viral partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors viral technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner?s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered ? contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual viral deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner?s flexibility on a wide range of important issues, many of which will have a significant impact on each party?s ability to derive value from the deal.

The initial chapters of this report provide an orientation of viral dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in viral dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading viral deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of viral deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all viral deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

For more information kindly visit :
Report on Viral Partnering Terms and Agreements

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Report on Partnering Agreements with Warner Chilcott 2005-2012

The Partnering Agreements with Warner Chilcott report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
This report provides all the information you require to better understand Warner Chilcott and its partnering interests and activities over the past five years.
On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.
The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

Description
This report provides all the information you require to better understand Warner Chilcott and its partnering interests and activities over the past seven years.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.

For more information kindly visit :
Report on Partnering Agreements with Warner Chilcott 2005-2012

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
http://3marketresearchreport.blogspot.in/

Tag Cloud